Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 4, 2011 Brian Orelli	VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market.
The Motley Fool September 16, 2011 Brian Orelli	A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa.
The Motley Fool September 21, 2010 Brian Orelli	Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool April 5, 2011 Brian Orelli	Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly.
The Motley Fool January 9, 2012 Brian Orelli	Don't Believe This Company's Warning VIVUS' news is great news.
The Motley Fool December 12, 2008 Brian Orelli	The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success?
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool July 16, 2010 Brian Orelli	Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa.
The Motley Fool July 13, 2010 Brian Orelli	A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight.
The Motley Fool September 9, 2009 Brian Orelli	Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa
The Motley Fool July 16, 2010 Luke Timmerman	Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics.
The Motley Fool June 3, 2011 Brian Orelli	FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool September 21, 2011 Brian Orelli	Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval.
The Motley Fool November 23, 2009 Brian Orelli	The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs.
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
The Motley Fool May 27, 2008 Brian Orelli	Livin' la Vivus Loca Irrational Exuberance for Vivus' Lead Drug Candidate?
The Motley Fool April 1, 2008 Brian Lawler	VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market.
The Motley Fool November 9, 2010 Brian Orelli	Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over.
The Motley Fool June 1, 2011 Brian Orelli	Not All "Regulatory Updates" Are the Good Kind Orexigen gives an update; investors update their holdings.
The Motley Fool October 19, 2010 Brian Orelli	Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency.
The Motley Fool September 17, 2010 Brian Orelli	Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile.
Chemistry World July 18, 2012 Andrew Turley	Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise.
The Motley Fool January 4, 2012 Brian Orelli	This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval.
The Motley Fool August 10, 2010 Brian Orelli	When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool July 16, 2010 Tom Hughes	Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity.
The Motley Fool February 1, 2011 Brian Orelli	Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon.
The Motley Fool April 30, 2007 Mike Havrilla	VIVUS Revives Investor Interest New drugs with huge markets could keep shares of VIVUS on their upward trajectory.
The Motley Fool September 18, 2009 Brian Orelli	Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug.
The Motley Fool July 14, 2010 Luke Timmerman	Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug
The Motley Fool March 30, 2011 Brian Orelli	This Share Count Might Need Some Obesity Meds Soon Arena gets some dilutive financing.
The Motley Fool October 25, 2010 Brian Orelli	Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know.
The Motley Fool March 17, 2011 Brian Orelli	Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues.
The Motley Fool December 22, 2010 Brian Orelli	Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is.
The Motley Fool December 22, 2010 Matt Koppenheffer	Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume.
The Motley Fool January 28, 2011 Brian Orelli	Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer.
The Motley Fool December 8, 2010 Brian Orelli	Up 100% With Room to Fly Orexigen gets a positive FDA panel nod.
The Motley Fool May 27, 2011 Brian Orelli	Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug.
The Motley Fool December 3, 2010 Brian Orelli	Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel.
The Motley Fool September 2, 2010 Brian Orelli	Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them.
The Motley Fool August 12, 2011 David Williamson	Does "FDA" Stand for "Faster Drug Approvals"? FDA approvals for 2011 just surpassed 2010.
The Motley Fool January 11, 2012 Dan Caplinger	Has Arena Pharmaceuticals Become the Perfect Stock? Since we looked at Arena Pharmaceuticals last year revenue has fallen back and debt-to-equity levels have soared.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
The Motley Fool December 30, 2011 Brian Orelli	Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing.
The Motley Fool March 30, 2009 Brian Orelli	Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration.
The Motley Fool June 3, 2011 Luke Timmerman	Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.